JDOC holdings
JPMorgan Healthcare Leaders ETF
Positions
61 stored of 61 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AbbVie, Inc. | US00287Y1091 | 00287Y109 | 7.848% | $712K | Equity (common) | Corporate | United States | USD |
| 2 | Eli Lilly & Co. | US5324571083 | 532457108 | 7.760% | $704K | Equity (common) | Corporate | United States | USD |
| 3 | UnitedHealth Group, Inc. | US91324P1021 | 91324P102 | 5.850% | $531K | Equity (common) | Corporate | United States | USD |
| 4 | Merck & Co., Inc. | US58933Y1055 | 58933Y105 | 4.819% | $437K | Equity (common) | Corporate | United States | USD |
| 5 | Johnson & Johnson | US4781601046 | 478160104 | 4.819% | $437K | Equity (common) | Corporate | United States | USD |
| 6 | AstraZeneca plc | GB0009895292 | Not reported | 3.762% | $341K | Equity (common) | Corporate | United Kingdom | GBP |
| 7 | Thermo Fisher Scientific, Inc. | US8835561023 | 883556102 | 3.734% | $339K | Equity (common) | Corporate | United States | USD |
| 8 | Bristol-Myers Squibb Co. | US1101221083 | 110122108 | 3.571% | $324K | Equity (common) | Corporate | United States | USD |
| 9 | Abbott Laboratories | US0028241000 | 002824100 | 3.109% | $282K | Equity (common) | Corporate | United States | USD |
| 10 | CVS Health Corp. | US1266501006 | 126650100 | 2.829% | $257K | Equity (common) | Corporate | United States | USD |
| 11 | Roche Holding AG | CH1499059983 | Not reported | 2.823% | $256K | Equity (common) | Corporate | Switzerland | CHF |
| 12 | Novo Nordisk A/S Novo Nordisk A/S, Class B | DK0062498333 | Not reported | 2.614% | $237K | Equity (common) | Corporate | Denmark | DKK |
| 13 | GSK plc | GB00BN7SWP63 | Not reported | 2.466% | $224K | Equity (common) | Corporate | United Kingdom | GBP |
| 14 | Stryker Corp. | US8636671013 | 863667101 | 2.225% | $202K | Equity (common) | Corporate | United States | USD |
| 15 | Danaher Corp. | US2358511028 | 235851102 | 2.161% | $196K | Equity (common) | Corporate | United States | USD |
| 16 | Cencora, Inc. | US03073E1055 | 03073E105 | 2.072% | $188K | Equity (common) | Corporate | United States | USD |
| 17 | Argenx SE | NL0010832176 | Not reported | 2.058% | $187K | Equity (common) | Corporate | Netherlands | EUR |
| 18 | Intuitive Surgical, Inc. | US46120E6023 | 46120E602 | 1.931% | $175K | Equity (common) | Corporate | United States | USD |
| 19 | Edwards Lifesciences Corp. | US28176E1082 | 28176E108 | 1.733% | $157K | Equity (common) | Corporate | United States | USD |
| 20 | IQVIA Holdings, Inc. | US46266C1053 | 46266C105 | 1.712% | $155K | Equity (common) | Corporate | United States | USD |
| 21 | Teva Pharmaceutical Industries Ltd. | IL0006290147 | Not reported | 1.601% | $145K | Equity (common) | Corporate | Israel | ILS |
| 22 | Regeneron Pharmaceuticals, Inc. | US75886F1075 | 75886F107 | 1.597% | $145K | Equity (common) | Corporate | United States | USD |
| 23 | Novartis AG Novartis AG (Registered) | CH0012005267 | Not reported | 1.596% | $145K | Equity (common) | Corporate | Switzerland | CHF |
| 24 | Biogen, Inc. | US09062X1037 | 09062X103 | 1.563% | $142K | Equity (common) | Corporate | United States | USD |
| 25 | Cardinal Health, Inc. | US14149Y1082 | 14149Y108 | 1.513% | $137K | Equity (common) | Corporate | United States | USD |
| 26 | Takeda Pharmaceutical Co. Ltd. | JP3463000004 | Not reported | 1.286% | $117K | Equity (common) | Corporate | Japan | JPY |
| 27 | Centene Corp. | US15135B1017 | 15135B101 | 1.193% | $108K | Equity (common) | Corporate | United States | USD |
| 28 | Hoya Corp. | JP3837800006 | Not reported | 1.180% | $107K | Equity (common) | Corporate | Japan | JPY |
| 29 | Humana, Inc. | US4448591028 | 444859102 | 1.163% | $106K | Equity (common) | Corporate | United States | USD |
| 30 | Boston Scientific Corp. | US1011371077 | 101137107 | 1.065% | $97K | Equity (common) | Corporate | United States | USD |
| 31 | Fresenius SE & Co. KGaA | DE0005785604 | Not reported | 1.037% | $94K | Equity (common) | Corporate | Germany | EUR |
| 32 | Insmed, Inc. | US4576693075 | 457669307 | 0.971% | $88K | Equity (common) | Corporate | United States | USD |
| 33 | Genmab A/S | DK0010272202 | Not reported | 0.834% | $76K | Equity (common) | Corporate | Denmark | DKK |
| 34 | Sartorius AG Sartorius AG (Preference) | DE0007165631 | Not reported | 0.828% | $75K | Equity (common) | Corporate | Germany | EUR |
| 35 | Dyne Therapeutics, Inc. | US26818M1080 | 26818M108 | 0.824% | $75K | Equity (common) | Corporate | United States | USD |
| 36 | Vertex Pharmaceuticals, Inc. | US92532F1003 | 92532F100 | 0.815% | $74K | Equity (common) | Corporate | United States | USD |
| 37 | Spyre Therapeutics, Inc. | US00773J2024 | 00773J202 | 0.769% | $70K | Equity (common) | Corporate | United States | USD |
| 38 | Neurocrine Biosciences, Inc. | US64125C1099 | 64125C109 | 0.733% | $67K | Equity (common) | Corporate | United States | USD |
| 39 | Bridgebio Pharma, Inc. | US10806X1028 | 10806X102 | 0.725% | $66K | Equity (common) | Corporate | United States | USD |
| 40 | Alnylam Pharmaceuticals, Inc. | US02043Q1076 | 02043Q107 | 0.704% | $64K | Equity (common) | Corporate | United States | USD |
| 41 | Align Technology, Inc. | US0162551016 | 016255101 | 0.701% | $64K | Equity (common) | Corporate | United States | USD |
| 42 | Charles River Laboratories International, Inc. | US1598641074 | 159864107 | 0.664% | $60K | Equity (common) | Corporate | United States | USD |
| 43 | CG oncology, Inc. | US1569441009 | 156944100 | 0.621% | $56K | Equity (common) | Corporate | United States | USD |
| 44 | Ascendis Pharma A/S | DK0060615755 | Not reported | 0.586% | $53K | Equity (common) | Corporate | Denmark | USD |
| 45 | Alumis, Inc. | US0223071020 | 022307102 | 0.571% | $52K | Equity (common) | Corporate | United States | USD |
| 46 | LB Pharmaceuticals, Inc. | US50180M1080 | 50180M108 | 0.556% | $50K | Equity (common) | Corporate | United States | USD |
| 47 | Disc Medicine, Inc. | US2546041011 | 254604101 | 0.509% | $46K | Equity (common) | Corporate | United States | USD |
| 48 | PTC Therapeutics, Inc. | US69366J2006 | 69366J200 | 0.493% | $45K | Equity (common) | Corporate | United States | USD |
| 49 | Bicara Therapeutics, Inc. | US0554771032 | 055477103 | 0.443% | $40K | Equity (common) | Corporate | United States | USD |
| 50 | Arcus Biosciences, Inc. | US03969F1093 | 03969F109 | 0.430% | $39K | Equity (common) | Corporate | United States | USD |
| 51 | Erasca, Inc. | US29479A1088 | 29479A108 | 0.391% | $36K | Equity (common) | Corporate | United States | USD |
| 52 | Damora Therapeutics, Inc. | KYG2646Y1044 | Not reported | 0.372% | $34K | Equity (common) | Corporate | Cayman Islands | USD |
| 53 | Medtronic plc | IE00BTN1Y115 | Not reported | 0.345% | $31K | Equity (common) | Corporate | Ireland | USD |
| 54 | Legend Biotech Corp. | US52490G1022 | 52490G102 | 0.315% | $29K | Equity (common) | Corporate | Cayman Islands | USD |
| 55 | Argenx SE | NL0010832176 | Not reported | 0.302% | $27K | Equity (common) | Corporate | Netherlands | EUR |
| 56 | Sionna Therapeutics, Inc. | US8294011080 | 829401108 | 0.011% | $990 | Equity (common) | Corporate | United States | USD |
| 57 | Japanese Yen | Not reported | Not reported | <0.001% | $48 | Short-term investment vehicles (cash funds) | Other | Japan | JPY |
| 58 | EURO Short position | Not reported | Not reported | −<0.001% | -$1 | Short-term investment vehicles (cash funds) | Other | Not stated or supranational | EUR |
| 59 | Swiss Franc | Not reported | Not reported | <0.001% | $0 | Short-term investment vehicles (cash funds) | Other | Switzerland | CHF |
| 60 | British Pound Short position | Not reported | Not reported | −<0.001% | -$0 | Short-term investment vehicles (cash funds) | Other | United Kingdom | GBP |
| 61 | Danish Krone Short position | Not reported | Not reported | 0.000% | $0 | Short-term investment vehicles (cash funds) | Other | Denmark | DKK |